Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat
Marijuana is known to have psychotropic effects in humans. In this study, we used rat models of sensorimotor gating, hyperactivity and stereotypy to explore whether CB(1) receptor stimulation or blockade induces behavioral changes consistent with psychotomimetic or antipsychotic agents, respectively...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacologia 2003, Vol.165 (2), p.128-135 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 2 |
| container_start_page | 128 |
| container_title | Psychopharmacologia |
| container_volume | 165 |
| creator | MARTIN, Renee S SECCHI, Robert L SUNG, Eric LEMAIRE, Martine BONHAUS, Douglas W HEDLEY, Linda R LOWE, David A |
| description | Marijuana is known to have psychotropic effects in humans. In this study, we used rat models of sensorimotor gating, hyperactivity and stereotypy to explore whether CB(1) receptor stimulation or blockade induces behavioral changes consistent with psychotomimetic or antipsychotic agents, respectively.
We determined whether (a) the cannabinoid agonist CP 55940 decreased pre-pulse inhibition (PPI) as might be expected from a psychotomimetic agent, and (b) the selective CB(1) receptor antagonist, SR 141716A, had any effect on PPI on its own or following disruptions by psychotomimetic agents. In addition, we investigated the effects of SR 141716A on elevated levels of hyperactivity and stereotypy elicited by d-amphetamine.
These studies were conducted in rats using standard methodologies for determination of PPI following acoustic stimuli, and d-amphetamine-induced hyperactivity and stereotypies.
Decreased startle responses to 120 dB stimuli were observed in rats treated with CP 55940 (0.1 mg/kg IP) in the absence and presence of a 73 dB pre-pulse. These effects were reversed by SR 141716A (5 and 10 mg/kg, respectively). SR 141716A (0.1, 5, 10 mg/kg) had no effect on PPI on its own or following disruptions by apomorphine, d-amphetamine or MK-801. Conversely, in separate experiments different antipsychotic agents reversed disruptions in PPI induced by d-amphetamine (haloperidol), apomorphine (haloperidol or clozapine) or MK-801 (clozapine or olanzapine). In addition, unlike haloperidol, SR 141716A (5 mg/kg) did not reverse d-amphetamine-mediated increases in hyperactivity or stereotypy.
The CP 55940-mediated decreases in startle amplitude confound assessment of the effects of CB(1) receptor activation on PPI. The failure of SR 141716A to reverse disruptions in PPI, hyperactivity or stereotypy induced by non-cannabinoid psychotomimetic agents suggests that blockade of the CB(1) receptor on its own is not sufficient for antipsychotic therapy. |
| doi_str_mv | 10.1007/s00213-002-1240-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18649752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>723531921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-3c31c03bb0d6f0792d9cc8dce02a2351af283f9ac433adcbcdceef70ce2cb7ae3</originalsourceid><addsrcrecordid>eNpd0FFLHDEQB_AgFb3afgBfJAj2LXaS7N5mH0W0LQh9aaFvITs78SJ7yZnsiX57c9yB0DxMHuY3w_Bn7FzCtQTovhcAJbWoVUjVgHg9YgvZaCUUdOoTWwBoLbRszSn7XMoT1NeY5oSd7nQDnVywf3feE86FJ8_RxeiGEFMYeSakzZwyn8Kji2PtR74pb7hKJRSRaaIXF2c-0Mq9hMrWaaSp8BD5vCKe3fyFHXs3Ffp6-M_Y3_u7P7c_xcPvH79ubx4EatPOQqOWCHoYYFx66Ho19ohmRALllG6l88po3ztstHYjDlhb5DtAUjh0jvQZ-7bfu8npeUtltutQkKbJRUrbYqVZNn3Xqgov_4NPaZtjvc0qaXrTmlZWJPcIcyolk7ebHNYuv1kJdpe53Wdua7W7FO1rnbk4LN4Oaxo_Jg4hV3B1AK6gm3x2EUP5cE1rYFkvfAdLvosw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218985851</pqid></control><display><type>article</type><title>Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>MARTIN, Renee S ; SECCHI, Robert L ; SUNG, Eric ; LEMAIRE, Martine ; BONHAUS, Douglas W ; HEDLEY, Linda R ; LOWE, David A</creator><creatorcontrib>MARTIN, Renee S ; SECCHI, Robert L ; SUNG, Eric ; LEMAIRE, Martine ; BONHAUS, Douglas W ; HEDLEY, Linda R ; LOWE, David A</creatorcontrib><description>Marijuana is known to have psychotropic effects in humans. In this study, we used rat models of sensorimotor gating, hyperactivity and stereotypy to explore whether CB(1) receptor stimulation or blockade induces behavioral changes consistent with psychotomimetic or antipsychotic agents, respectively.
We determined whether (a) the cannabinoid agonist CP 55940 decreased pre-pulse inhibition (PPI) as might be expected from a psychotomimetic agent, and (b) the selective CB(1) receptor antagonist, SR 141716A, had any effect on PPI on its own or following disruptions by psychotomimetic agents. In addition, we investigated the effects of SR 141716A on elevated levels of hyperactivity and stereotypy elicited by d-amphetamine.
These studies were conducted in rats using standard methodologies for determination of PPI following acoustic stimuli, and d-amphetamine-induced hyperactivity and stereotypies.
Decreased startle responses to 120 dB stimuli were observed in rats treated with CP 55940 (0.1 mg/kg IP) in the absence and presence of a 73 dB pre-pulse. These effects were reversed by SR 141716A (5 and 10 mg/kg, respectively). SR 141716A (0.1, 5, 10 mg/kg) had no effect on PPI on its own or following disruptions by apomorphine, d-amphetamine or MK-801. Conversely, in separate experiments different antipsychotic agents reversed disruptions in PPI induced by d-amphetamine (haloperidol), apomorphine (haloperidol or clozapine) or MK-801 (clozapine or olanzapine). In addition, unlike haloperidol, SR 141716A (5 mg/kg) did not reverse d-amphetamine-mediated increases in hyperactivity or stereotypy.
The CP 55940-mediated decreases in startle amplitude confound assessment of the effects of CB(1) receptor activation on PPI. The failure of SR 141716A to reverse disruptions in PPI, hyperactivity or stereotypy induced by non-cannabinoid psychotomimetic agents suggests that blockade of the CB(1) receptor on its own is not sufficient for antipsychotic therapy.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-002-1240-x</identifier><identifier>PMID: 12404071</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Antipsychotic Agents - pharmacology ; Apomorphine - pharmacology ; Arousal - drug effects ; Arousal - physiology ; Attention - drug effects ; Attention - physiology ; Behavior, Animal - drug effects ; Behavior, Animal - physiology ; Biological and medical sciences ; Cyclohexanols - pharmacology ; Dextroamphetamine - pharmacology ; Dizocilpine Maleate - pharmacology ; Dose-Response Relationship, Drug ; Drug addictions ; Hallucinogens - pharmacology ; Male ; Medical sciences ; Motor Activity - drug effects ; Motor Activity - physiology ; Piperidines - pharmacology ; Psychoses, Substance-Induced - physiopathology ; Psychosis ; Pyrazoles - pharmacology ; Rats ; Rats, Wistar ; Receptors, Cannabinoid ; Receptors, Drug - drug effects ; Receptors, Drug - physiology ; Reflex, Startle - drug effects ; Stereotyped Behavior - drug effects ; Stereotyped Behavior - physiology ; Toxicology</subject><ispartof>Psychopharmacologia, 2003, Vol.165 (2), p.128-135</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-3c31c03bb0d6f0792d9cc8dce02a2351af283f9ac433adcbcdceef70ce2cb7ae3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14580652$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12404071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MARTIN, Renee S</creatorcontrib><creatorcontrib>SECCHI, Robert L</creatorcontrib><creatorcontrib>SUNG, Eric</creatorcontrib><creatorcontrib>LEMAIRE, Martine</creatorcontrib><creatorcontrib>BONHAUS, Douglas W</creatorcontrib><creatorcontrib>HEDLEY, Linda R</creatorcontrib><creatorcontrib>LOWE, David A</creatorcontrib><title>Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>Marijuana is known to have psychotropic effects in humans. In this study, we used rat models of sensorimotor gating, hyperactivity and stereotypy to explore whether CB(1) receptor stimulation or blockade induces behavioral changes consistent with psychotomimetic or antipsychotic agents, respectively.
We determined whether (a) the cannabinoid agonist CP 55940 decreased pre-pulse inhibition (PPI) as might be expected from a psychotomimetic agent, and (b) the selective CB(1) receptor antagonist, SR 141716A, had any effect on PPI on its own or following disruptions by psychotomimetic agents. In addition, we investigated the effects of SR 141716A on elevated levels of hyperactivity and stereotypy elicited by d-amphetamine.
These studies were conducted in rats using standard methodologies for determination of PPI following acoustic stimuli, and d-amphetamine-induced hyperactivity and stereotypies.
Decreased startle responses to 120 dB stimuli were observed in rats treated with CP 55940 (0.1 mg/kg IP) in the absence and presence of a 73 dB pre-pulse. These effects were reversed by SR 141716A (5 and 10 mg/kg, respectively). SR 141716A (0.1, 5, 10 mg/kg) had no effect on PPI on its own or following disruptions by apomorphine, d-amphetamine or MK-801. Conversely, in separate experiments different antipsychotic agents reversed disruptions in PPI induced by d-amphetamine (haloperidol), apomorphine (haloperidol or clozapine) or MK-801 (clozapine or olanzapine). In addition, unlike haloperidol, SR 141716A (5 mg/kg) did not reverse d-amphetamine-mediated increases in hyperactivity or stereotypy.
The CP 55940-mediated decreases in startle amplitude confound assessment of the effects of CB(1) receptor activation on PPI. The failure of SR 141716A to reverse disruptions in PPI, hyperactivity or stereotypy induced by non-cannabinoid psychotomimetic agents suggests that blockade of the CB(1) receptor on its own is not sufficient for antipsychotic therapy.</description><subject>Animals</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Apomorphine - pharmacology</subject><subject>Arousal - drug effects</subject><subject>Arousal - physiology</subject><subject>Attention - drug effects</subject><subject>Attention - physiology</subject><subject>Behavior, Animal - drug effects</subject><subject>Behavior, Animal - physiology</subject><subject>Biological and medical sciences</subject><subject>Cyclohexanols - pharmacology</subject><subject>Dextroamphetamine - pharmacology</subject><subject>Dizocilpine Maleate - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug addictions</subject><subject>Hallucinogens - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Motor Activity - drug effects</subject><subject>Motor Activity - physiology</subject><subject>Piperidines - pharmacology</subject><subject>Psychoses, Substance-Induced - physiopathology</subject><subject>Psychosis</subject><subject>Pyrazoles - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Cannabinoid</subject><subject>Receptors, Drug - drug effects</subject><subject>Receptors, Drug - physiology</subject><subject>Reflex, Startle - drug effects</subject><subject>Stereotyped Behavior - drug effects</subject><subject>Stereotyped Behavior - physiology</subject><subject>Toxicology</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0FFLHDEQB_AgFb3afgBfJAj2LXaS7N5mH0W0LQh9aaFvITs78SJ7yZnsiX57c9yB0DxMHuY3w_Bn7FzCtQTovhcAJbWoVUjVgHg9YgvZaCUUdOoTWwBoLbRszSn7XMoT1NeY5oSd7nQDnVywf3feE86FJ8_RxeiGEFMYeSakzZwyn8Kji2PtR74pb7hKJRSRaaIXF2c-0Mq9hMrWaaSp8BD5vCKe3fyFHXs3Ffp6-M_Y3_u7P7c_xcPvH79ubx4EatPOQqOWCHoYYFx66Ho19ohmRALllG6l88po3ztstHYjDlhb5DtAUjh0jvQZ-7bfu8npeUtltutQkKbJRUrbYqVZNn3Xqgov_4NPaZtjvc0qaXrTmlZWJPcIcyolk7ebHNYuv1kJdpe53Wdua7W7FO1rnbk4LN4Oaxo_Jg4hV3B1AK6gm3x2EUP5cE1rYFkvfAdLvosw</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>MARTIN, Renee S</creator><creator>SECCHI, Robert L</creator><creator>SUNG, Eric</creator><creator>LEMAIRE, Martine</creator><creator>BONHAUS, Douglas W</creator><creator>HEDLEY, Linda R</creator><creator>LOWE, David A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>2003</creationdate><title>Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat</title><author>MARTIN, Renee S ; SECCHI, Robert L ; SUNG, Eric ; LEMAIRE, Martine ; BONHAUS, Douglas W ; HEDLEY, Linda R ; LOWE, David A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-3c31c03bb0d6f0792d9cc8dce02a2351af283f9ac433adcbcdceef70ce2cb7ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Apomorphine - pharmacology</topic><topic>Arousal - drug effects</topic><topic>Arousal - physiology</topic><topic>Attention - drug effects</topic><topic>Attention - physiology</topic><topic>Behavior, Animal - drug effects</topic><topic>Behavior, Animal - physiology</topic><topic>Biological and medical sciences</topic><topic>Cyclohexanols - pharmacology</topic><topic>Dextroamphetamine - pharmacology</topic><topic>Dizocilpine Maleate - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug addictions</topic><topic>Hallucinogens - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Motor Activity - drug effects</topic><topic>Motor Activity - physiology</topic><topic>Piperidines - pharmacology</topic><topic>Psychoses, Substance-Induced - physiopathology</topic><topic>Psychosis</topic><topic>Pyrazoles - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Cannabinoid</topic><topic>Receptors, Drug - drug effects</topic><topic>Receptors, Drug - physiology</topic><topic>Reflex, Startle - drug effects</topic><topic>Stereotyped Behavior - drug effects</topic><topic>Stereotyped Behavior - physiology</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MARTIN, Renee S</creatorcontrib><creatorcontrib>SECCHI, Robert L</creatorcontrib><creatorcontrib>SUNG, Eric</creatorcontrib><creatorcontrib>LEMAIRE, Martine</creatorcontrib><creatorcontrib>BONHAUS, Douglas W</creatorcontrib><creatorcontrib>HEDLEY, Linda R</creatorcontrib><creatorcontrib>LOWE, David A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MARTIN, Renee S</au><au>SECCHI, Robert L</au><au>SUNG, Eric</au><au>LEMAIRE, Martine</au><au>BONHAUS, Douglas W</au><au>HEDLEY, Linda R</au><au>LOWE, David A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2003</date><risdate>2003</risdate><volume>165</volume><issue>2</issue><spage>128</spage><epage>135</epage><pages>128-135</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Marijuana is known to have psychotropic effects in humans. In this study, we used rat models of sensorimotor gating, hyperactivity and stereotypy to explore whether CB(1) receptor stimulation or blockade induces behavioral changes consistent with psychotomimetic or antipsychotic agents, respectively.
We determined whether (a) the cannabinoid agonist CP 55940 decreased pre-pulse inhibition (PPI) as might be expected from a psychotomimetic agent, and (b) the selective CB(1) receptor antagonist, SR 141716A, had any effect on PPI on its own or following disruptions by psychotomimetic agents. In addition, we investigated the effects of SR 141716A on elevated levels of hyperactivity and stereotypy elicited by d-amphetamine.
These studies were conducted in rats using standard methodologies for determination of PPI following acoustic stimuli, and d-amphetamine-induced hyperactivity and stereotypies.
Decreased startle responses to 120 dB stimuli were observed in rats treated with CP 55940 (0.1 mg/kg IP) in the absence and presence of a 73 dB pre-pulse. These effects were reversed by SR 141716A (5 and 10 mg/kg, respectively). SR 141716A (0.1, 5, 10 mg/kg) had no effect on PPI on its own or following disruptions by apomorphine, d-amphetamine or MK-801. Conversely, in separate experiments different antipsychotic agents reversed disruptions in PPI induced by d-amphetamine (haloperidol), apomorphine (haloperidol or clozapine) or MK-801 (clozapine or olanzapine). In addition, unlike haloperidol, SR 141716A (5 mg/kg) did not reverse d-amphetamine-mediated increases in hyperactivity or stereotypy.
The CP 55940-mediated decreases in startle amplitude confound assessment of the effects of CB(1) receptor activation on PPI. The failure of SR 141716A to reverse disruptions in PPI, hyperactivity or stereotypy induced by non-cannabinoid psychotomimetic agents suggests that blockade of the CB(1) receptor on its own is not sufficient for antipsychotic therapy.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>12404071</pmid><doi>10.1007/s00213-002-1240-x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacologia, 2003, Vol.165 (2), p.128-135 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18649752 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animals Antipsychotic Agents - pharmacology Apomorphine - pharmacology Arousal - drug effects Arousal - physiology Attention - drug effects Attention - physiology Behavior, Animal - drug effects Behavior, Animal - physiology Biological and medical sciences Cyclohexanols - pharmacology Dextroamphetamine - pharmacology Dizocilpine Maleate - pharmacology Dose-Response Relationship, Drug Drug addictions Hallucinogens - pharmacology Male Medical sciences Motor Activity - drug effects Motor Activity - physiology Piperidines - pharmacology Psychoses, Substance-Induced - physiopathology Psychosis Pyrazoles - pharmacology Rats Rats, Wistar Receptors, Cannabinoid Receptors, Drug - drug effects Receptors, Drug - physiology Reflex, Startle - drug effects Stereotyped Behavior - drug effects Stereotyped Behavior - physiology Toxicology |
| title | Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A27%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20cannabinoid%20receptor%20ligands%20on%20psychosis-relevant%20behavior%20models%20in%20the%20rat&rft.jtitle=Psychopharmacologia&rft.au=MARTIN,%20Renee%20S&rft.date=2003&rft.volume=165&rft.issue=2&rft.spage=128&rft.epage=135&rft.pages=128-135&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-002-1240-x&rft_dat=%3Cproquest_cross%3E723531921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218985851&rft_id=info:pmid/12404071&rfr_iscdi=true |